NCT00348946

Androgen Effect on Klinefelter Syndrome Motor Outcome

Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Thomas Jefferson University · Academic / Other
• Sex: Male
• Age: 4 Years – 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of low-dose androgen on the motor and cognitive development of boys with Klinefelter syndrome.

Detailed description

Klinefelter syndrome (KS), a genetic disorder that affects males only, is characterized by having an extra X chromosome. The phenotype - or physical and learning features - includes testicular failure, tall stature, and specific cognitive and behavioral attributes such as diminished motor function, language-based learning difficulties, poor self-image, and shyness. The KS phenotype may be the result of androgen deficiency in utero, infancy, and childhood. For individuals with KS, androgen replacement is standard treatment in adolescence and adulthood but has not been used earlier in childhood or included in the standard medical care of KS children ages 4 to 12. The purpose of this study is to examine the effects of androgen on learning and development in boys with KS. Researchers also want to determine if low-dose androgen replacement at an early age will improve some of the learning difficulties associated with the disorder. The overall goal of this study is to address questions regarding the relationship of early androgen deficiency to learning and motor function. Participants in the study will be randomized to one of two treatment groups, receiving either oxandrolone (low-dose androgen) or placebo, for two years. All participants will be evaluated for safety at the beginning of the study and at 3, 6, 12, 18, and 24 months. Also at the beginning of the study and every 3 to 6 months thereafter (for a total of 6 visits), the researchers will perform a careful history and physical examination and a bone age X-ray, and obtain a blood sample. Participation in the trial will last two years and includes 6 clinic visits.

Conditions

• Klinefelter Syndrome

Interventions

Type	Name	Description
DRUG	androgen oxandrolone	Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
OTHER	placebo	an inactive substance

Timeline

• Start date: 2006-07-01
• Primary completion: 2017-11-30
• Completion: 2017-11-30
• First posted: 2006-07-06
• Last updated: 2021-07-08
• Results posted: 2021-07-08

Locations

1 site across 1 country: United States